首页 › 基金 › Octagon Capital Advisors LP › ERAS
Octagon Capital Advisors LP 对 ERAS 的持仓历史
ERASCA INC · 医疗保健
Octagon Capital Advisors LP 在 Q3 2026 的 13F 申报中披露持有 ERAS(ERASCA INC)720,000 股,市值约 US$10.6M,约占其申报组合的 1.41%,在其申报持仓中市值排名第 16 位。 Octagon Capital Advisors LP 最近 8 个申报季度中有 5 个季度披露了 ERAS 持仓,最早可追溯至 Q4 2024。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Octagon Capital Advisors LP 对 ERAS 的持仓演变
Octagon Capital Advisors LP 于 Q4 2024 首次披露 ERAS 持仓:5,136,795 股(约 US$12.9M)。 该持仓在 Q2 2026 达到峰值 1,255,000 股,市值约 US$23.0M。 在 5 次申报中,Octagon Capital Advisors LP 0 次增持、2 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 720,000 股、市值约 US$10.6M,环比减持 -535,000 股。。 持仓曾出现大幅变动:Q2 2025 减持约 86% (随后一个季度股价上涨 72%)、Q3 2026 减持约 43% (随后一个季度股价上涨 3%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2024 | 5.14M | $12.89M | 新进 |
| Q1 2025 | 5.14M | $7.04M | 持有 |
| Q2 2025 | 700.00K | $889.00K | 减持 |
| Q2 2026 | 1.25M | $22.99M | 新进 |
| Q3 2026 | 720.00K | $10.56M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 ERAS 与 13F 数据
ERAS(ERASCA INC)属于医疗保健行业。我们追踪的基金中还有 63 只申报持有 ERAS,申报仓位最大的包括:Frazier Life Sciences Management, L.P. (US$432.1M), RTW INVESTMENTS, LP (US$329.1M), Venrock Adviser, LLC (US$294.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 ERAS 的基金
- Frazier Life Sciences Management, L.P. 29.48M 股 · $432.11M · Q3 2026
- RTW INVESTMENTS, LP 22.45M 股 · $329.07M · Q3 2026
- Venrock Adviser, LLC 20.09M 股 · $294.52M · Q3 2026
- Siren, L.L.C. 13.20M 股 · $193.48M · Q3 2026
- Paradigm Biocapital Advisors LP 8.00M 股 · $117.25M · Q3 2026
- ARCH Venture Management, LLC 7.09M 股 · $103.96M · Q3 2026
- Affinity Asset Advisors, LLC 5.59M 股 · $81.96M · Q3 2026
- Soleus Capital Management, L.P. 5.11M 股 · $74.94M · Q3 2026
- Cormorant Asset Management, LP 5.00M 股 · $73.30M · Q3 2026
- Vivo Capital, LLC 4.02M 股 · $58.94M · Q3 2026
- EcoR1 Capital, LLC 2.95M 股 · $43.25M · Q3 2026
- SAMLYN CAPITAL, LLC 2.54M 股 · $37.29M · Q3 2026
更多关于 Octagon Capital Advisors LP
常见问题
How long has Octagon Capital Advisors LP held ERAS?
Octagon Capital Advisors LP has disclosed ERAS holdings in 5 of the last 8 reported quarters, going back to Q4 2024.
What is Octagon Capital Advisors LP's current position in ERAS?
As of Q3 2026, Octagon Capital Advisors LP holds 720.00K shares of ERAS (ERASCA INC), valued at $10.56M, representing 1.41% of its reported portfolio and ranking #16.
Has Octagon Capital Advisors LP been buying or selling ERAS?
In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP reduced its position in ERAS. The position peaked in Q2 2026 at 1.25M shares.
Which other funds hold ERAS?
Other major institutional holders of ERAS include Frazier Life Sciences Management, L.P., RTW INVESTMENTS, LP, Venrock Adviser, LLC, among 63 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.